KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $69.4 million.

  • Inovio Pharmaceuticals' Liabilities and Shareholders Equity fell 3518.97% to $69.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.1 million, marking a year-over-year decrease of 3749.64%. This contributed to the annual value of $113.2 million for FY2024, which is 3378.4% down from last year.
  • Per Inovio Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $69.4 million for Q3 2025, which was down 3518.97% from $68.2 million recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $654.9 million during Q1 2021, and its lowest value of $68.2 million during Q2 2025.
  • Its 5-year average for Liabilities and Shareholders Equity is $289.2 million, with a median of $233.0 million in 2023.
  • As far as peak fluctuations go, Inovio Pharmaceuticals' Liabilities and Shareholders Equity skyrocketed by 9322.02% in 2021, and later crashed by 5156.69% in 2024.
  • Over the past 5 years, Inovio Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $495.9 million in 2021, then decreased by 29.72% to $348.5 million in 2022, then tumbled by 50.95% to $171.0 million in 2023, then tumbled by 33.78% to $113.2 million in 2024, then plummeted by 38.7% to $69.4 million in 2025.
  • Its last three reported values are $69.4 million in Q3 2025, $68.2 million for Q2 2025, and $87.3 million during Q1 2025.